These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 12939225)

  • 21. Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury.
    Schäfer K; Kaiser K; Konstantinides S
    Thromb Haemost; 2005 Jan; 93(1):145-52. PubMed ID: 15630505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rosuvastatin Reduces Aortic Sinus and Coronary Artery Atherosclerosis in SR-B1 (Scavenger Receptor Class B Type 1)/ApoE (Apolipoprotein E) Double Knockout Mice Independently of Plasma Cholesterol Lowering.
    Yu P; Xiong T; Tenedero CB; Lebeau P; Ni R; MacDonald ME; Gross PL; Austin RC; Trigatti BL
    Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):26-39. PubMed ID: 29162602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia.
    Pirro M; Schillaci G; Mannarino MR; Savarese G; Vaudo G; Siepi D; Paltriccia R; Mannarino E
    Nutr Metab Cardiovasc Dis; 2007 Jul; 17(6):436-41. PubMed ID: 17134956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan.
    Chen J; Li D; Schaefer R; Mehta JL
    Atherosclerosis; 2006 Feb; 184(2):295-301. PubMed ID: 16005008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
    Deguchi I; Horiuchi Y; Hayashi T; Sehara Y; Kato Y; Ohe Y; Fukuoka T; Maruyama H; Sano H; Nagamine Y; Tanahashi N
    J Stroke Cerebrovasc Dis; 2014 Sep; 23(8):2007-2011. PubMed ID: 25066602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rosuvastatin restores superoxide dismutase expression and inhibits accumulation of oxidized LDL in the aortic arch of obese dyslipidemic mice.
    Verreth W; De Keyzer D; Davey PC; Geeraert B; Mertens A; Herregods MC; Smith G; Desjardins F; Balligand JL; Holvoet P
    Br J Pharmacol; 2007 Jun; 151(3):347-55. PubMed ID: 17384667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering.
    Sparrow CP; Burton CA; Hernandez M; Mundt S; Hassing H; Patel S; Rosa R; Hermanowski-Vosatka A; Wang PR; Zhang D; Peterson L; Detmers PA; Chao YS; Wright SD
    Arterioscler Thromb Vasc Biol; 2001 Jan; 21(1):115-21. PubMed ID: 11145942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenetic determinants of statin-induced reductions in C-reactive protein.
    Chu AY; Guilianini F; Barratt BJ; Nyberg F; Chasman DI; Ridker PM
    Circ Cardiovasc Genet; 2012 Feb; 5(1):58-65. PubMed ID: 22230323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid.
    Stalker TJ; Lefer AM; Scalia R
    Br J Pharmacol; 2001 Jun; 133(3):406-12. PubMed ID: 11375257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-inflammatory salicylate beneficially modulates pre-existing atherosclerosis through quenching of NF-κB activity and lowering of cholesterol.
    de Vries-van der Weij J; Toet K; Zadelaar S; Wielinga PY; Kleemann R; Rensen PC; Kooistra T
    Atherosclerosis; 2010 Nov; 213(1):241-6. PubMed ID: 20926077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rosuvastatin attenuates atherosclerosis in rats via activation of scavenger receptor class B type I.
    Li Y; Wang Q; Zhou J; Xu Q; Chu X; Sun T; Liu X; Cai S
    Eur J Pharmacol; 2014 Jan; 723():23-8. PubMed ID: 24333476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes.
    Betteridge DJ; Gibson JM
    Diabet Med; 2007 May; 24(5):541-9. PubMed ID: 17367312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of rosuvastatin on cardiovascular morphology and function in an ApoE-knockout mouse model of atherosclerosis.
    Grönros J; Wikström J; Brandt-Eliasson U; Forsberg GB; Behrendt M; Hansson GI; Gan LM
    Am J Physiol Heart Circ Physiol; 2008 Nov; 295(5):H2046-53. PubMed ID: 18790840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of intensive lipid lowering on lipid profiles over time and tolerability in stable coronary artery disease: insights from a subanalysis of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS).
    Kawashiri MA; Yamagishi M; Sakamoto T; Takayama T; Hiro T; Daida H; Hirayama A; Saito S; Yamaguchi T; Matsuzaki M;
    Cardiovasc Ther; 2013 Dec; 31(6):335-43. PubMed ID: 23409830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial.
    Tam LS; Li EK; Shang Q; Tomlinson B; Lee VW; Lee KK; Li M; Kuan WP; Li TK; Tseung L; Yip GW; Freedman B; Yu CM
    Scand J Rheumatol; 2011 Nov; 40(6):411-21. PubMed ID: 21867445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soybean glycinin improves HDL-C and suppresses the effects of rosuvastatin on hypercholesterolemic rats.
    Fassini PG; Noda RW; Ferreira ES; Silva MA; Neves VA; Demonte A
    Lipids Health Dis; 2011 Sep; 10():165. PubMed ID: 21936891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.
    Olsson AG; McTaggart F; Raza A
    Cardiovasc Drug Rev; 2002; 20(4):303-28. PubMed ID: 12481202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rosuvastatin reduces atherosclerotic lesions and promotes progenitor cell mobilisation and recruitment in apolipoprotein E knockout mice.
    Schroeter MR; Humboldt T; Schäfer K; Konstantinides S
    Atherosclerosis; 2009 Jul; 205(1):63-73. PubMed ID: 19111832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of atherosclerotic lesions in apo E3-leiden transgenic mice.
    Leppänen P; Luoma JS; Hofker MH; Havekes LM; Ylä-Herttuala S
    Atherosclerosis; 1998 Jan; 136(1):147-52. PubMed ID: 9544741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.